⁸⁹Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem Cell Targeted Therapy

References

• Cardoso F, Spence D, Mertz S, et al. Global analysis of advanced/metastatic breast cancer: decade report (20052015). Breast. 2018;39:131–138. doi:10.1016/j.breast.2018.03.00229679849
   PubMed Web of Science ®Google Scholar
• Shah TA, Guraya SS. Breast cancer screening programs: review of merits, demerits, and recent recommendations practiced across the world. J Microscopy Ultrastructure. 2017;5(2):59–69. doi:10.1016/j.jmau.2016.10.002
   PubMedGoogle Scholar
• Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674–690. doi:10.1038/nrclinonc.2016.6627184417
   PubMed Web of Science ®Google Scholar
• Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124–1134. doi:10.1038/nm.440928985214
   PubMed Web of Science ®Google Scholar
• Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology. 2014;28(12):1101–1107, 1110.25510809
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–3988. doi:10.1073/pnas.053029110012629218
   PubMed Web of Science ®Google Scholar
• Zheng Z, Shao N, Weng H, et al. Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma. Medical Oncol. 2015;32(1):275. doi:10.1007/s12032-014-0275-2
   PubMed Web of Science ®Google Scholar
• Wang H, Wang L, Song Y, et al. CD44(+)/CD24(-) phenotype predicts a poor prognosis in triple-negative breast cancer. Oncol Lett. 2017;14(5):5890–5898.29113223
   PubMed Web of Science ®Google Scholar
• Pandey S, Mahtab A, Rai N, Rawat P, Ahmad FJ, Talegaonkar S. Emerging role of CD44 receptor as a potential target in disease diagnosis: a patent review. Recent Pat Inflamm Allergy Drug Discov. 2017;11(2):77–91. doi:10.2174/1872213X1166617090711185828891438
   PubMedGoogle Scholar
• Morath I, Hartmann TN, Orian-Rousseau V. CD44: more than a mere stem cell marker. Int J Biochem Cell Biol. 2016;81(Pt A):166–173. doi:10.1016/j.biocel.2016.09.00927640754
   PubMedGoogle Scholar
• Rao W, Wang H, Han J, et al. Chitosan-decorated doxorubicin-encapsulated nanoparticle targets and eliminates tumor reinitiating cancer stem-like cells. ACS Nano. 2015;9(6):5725–5740.26004286
   PubMed Web of Science ®Google Scholar
• Zhang X, Li F, Zheng Y, et al. Propofol reduced mammosphere formation of breast cancer stem cells via PD-L1/Nanog in vitro. Oxid Med Cell Longev. 2019;2019:9078209.30906504
   PubMed Web of Science ®Google Scholar
• Cioce M, Gherardi S, Viglietto G, et al. Mammosphere-forming cells from breast cancer cell lines as a tool for the identification of CSC-like- and early progenitor-targeting drugs. Cell Cycle. 2010;9(14):2878–2887. doi:10.4161/cc.9.14.1237120581442
   PubMed Web of Science ®Google Scholar
• Moore-Smith L, Forero-Torres A, Stringer-Reasor E. Future developments in neoadjuvant therapy for triple-negative breast cancer. Surg Clin North Am. 2018;98(4):773–785. doi:10.1016/j.suc.2018.04.00430005773
   PubMed Web of Science ®Google Scholar
• Diaz Casas S, Lancheros Garcia E, Sanchez Campo A, et al. Clinical behavior of triple negative breast cancer in a cohort of latin american women. Cureus. 2019;11(6):e4963.31453035
   PubMed Web of Science ®Google Scholar
• Gao J, Li W, Guo Y, Feng SS. Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine. 2016;11(24):3261–3282. doi:10.2217/nnm-2016-026127854161
   PubMed Web of Science ®Google Scholar
• Zhao D, Yu S, Sun B, Gao S, Guo S, Zhao K. Biomedical applications of chitosan and its derivative nanoparticles. Polymers. 2018;10:4. doi:10.3390/polym10040462
   Web of Science ®Google Scholar
• Kim UJ, Lee YR, Kang TH, Choi JW, Kimura S, Wada M. Protein adsorption of dialdehyde cellulose-crosslinked chitosan with high amino group contents. Carbohydr Polym. 2017;163:34–42. doi:10.1016/j.carbpol.2017.01.05228267516
   PubMed Web of Science ®Google Scholar
• Fenaroli F, Repnik U, Xu Y, et al. Enhanced permeability and retention-like extravasation of nanoparticles from the vasculature into tuberculosis granulomas in zebrafish and mouse models. ACS Nano. 2018;12(8):8646–8661. doi:10.1021/acsnano.8b0443330081622
   PubMed Web of Science ®Google Scholar
• Muppidi K, Pumerantz AS, Wang J, Betageri G. Development and stability studies of novel liposomal vancomycin formulations. ISRN Pharm. 2012;2012:636743. doi:10.5402/2012/63674322500244
   PubMedGoogle Scholar
• Yu B, Goel S, Ni D, et al. Reassembly of 89Zr-labeled cancer cell membranes into multicompartment membrane-derived liposomes for pet-trackable tumor-targeted theranostics. Adv Mater. 2018;30(13):e1704934. doi:10.1002/adma.20170493429430735
   PubMed Web of Science ®Google Scholar
• Samuelsson E, Shen H, Blanco E, Ferrari M, Wolfram J. Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces. 2017;158:356–362. doi:10.1016/j.colsurfb.2017.07.01428719856
   PubMed Web of Science ®Google Scholar
• Wang X, Chen W. Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem. 2012;12(8):994–1000. doi:10.2174/18715201280265006622339063
   PubMed Web of Science ®Google Scholar
• Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64. doi:10.1186/s13045-018-0605-529747682
   PubMed Web of Science ®Google Scholar
• Wickens JM, Alsaab HO, Kesharwani P, et al. Recent advances in hyaluronic acid-decorated nanocarriers for targeted cancer therapy. Drug Discov Today. 2017;22(4):665–680. doi:10.1016/j.drudis.2016.12.00928017836
   PubMed Web of Science ®Google Scholar
• Fischer G, Seibold U, Schirrmacher R, Wangler B, Wangler C. (89) Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges. Molecules. 2013;18(6):6469–6490. doi:10.3390/molecules1806646923736785
   PubMed Web of Science ®Google Scholar
• Patel HJ, Patel BM. TNF-α and cancer cachexia: molecular insights and clinical implications. Life Sci. 2017;170:56–63. doi:10.1016/j.lfs.2016.11.03327919820
   PubMed Web of Science ®Google Scholar
• Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Molecular Med. 2016;94(5):509–522. doi:10.1007/s00109-015-1376-x
   PubMed Web of Science ®Google Scholar
• Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049–6058. doi:10.2147/IJN.S14046230323592
   PubMed Web of Science ®Google Scholar